TOP TEN perturbations for 39532_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39532_at
Selected probe(set): 205211_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39532_at (205211_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):3.2320938Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (lesional; whole skin) |
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal skin tissue |
Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):3.11028Number of Samples:5 / 6
Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
Control | normal skin tissue |
Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):2.2926607Number of Samples:20 / 19
Experimental | atopic dermatitis study 12 (non-lesional; adults) |
Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | atopic dermatitis study 12 (non-lesional; children) |
Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):2.1320076Number of Samples:20 / 18
Experimental | atopic dermatitis study 12 (lesional; adults) |
Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
Control | atopic dermatitis study 12 (lesional; children) |
Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample
Relative Expression (log2-ratio):2.0631676Number of Samples:11 / 6
Experimental | ovarian tumor study 11 (low grade) |
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
Control | normal ovarian surface epithelial cell sample |
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):2.0551586Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
dimethyloxalylglycine study 2 (175140ng/ml) / vehicle (DME) treated bronchial epithelial cell sample
Relative Expression (log2-ratio):-1.7954111Number of Samples:3 / 17
Experimental | dimethyloxalylglycine study 2 (175140ng/ml) |
Bronchial epithelial cells (NHBE) treated with dimethyloxalylglycine (175140ng/ml; vendor: Cayman Chemical / catalog number: CAYM71210-10 / catalog name: dimethyloxallyl glycine) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:--- | |
Control | vehicle (DME) treated bronchial epithelial cell sample |
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):-1.7443037Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
ovarian tumor study 11 (high grade) / ovarian tumor study 11 (low grade)
Relative Expression (log2-ratio):-1.7250128Number of Samples:22 / 11
Experimental | ovarian tumor study 11 (high grade) |
Human microdissected tumor cells from the ovary of patients with high grade serous carcinoma. | |
Control | ovarian tumor study 11 (low grade) |
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. |
CD44s overexpr. study 1 / normal HEK-293 cell sample
Relative Expression (log2-ratio):1.6679907Number of Samples:3 / 3
Experimental | CD44s overexpr. study 1 |
Human embryonic kidney cell line HEK-293 transfected with pcDNA3.1(-) vector containing codon-optimized human CD44 sequence for expression. | |
Control | normal HEK-293 cell sample |
Untransfected, native human embryonic kidney cell line HEK-293 cell samples. |